Effect of priming interval on reactogenicity, peak immunological response, and waning after homologous and heterologous COVID-19 vaccine schedules: exploratory analyses of Com-COV, a randomised control trialRandomized Controlled Trial Published on 2022-06-092022-10-05 Journal: The Lancet. Respiratory Medicine [Category] COVID19(2023년), SARS, 유전자 메커니즘, 임상, 진단, [키워드] 95% CI addition Adjusted analysis anti-SARS-CoV-2 anti-Spike IgG Antibody Response assigned AstraZeneca baseline benefit BNT162b2 booster Cellular immune response ChAdOx1 ChAdOx1 nCoV-19 Cohort COVID-19 vaccine dose Effect eight EudraCT Evidence Exploratory analyses Exploratory analysis finding funding Future geometric mean concentration geometric mean ratio group groups Heterologous heterologous vaccine homologous humoral humoral immunogenicity immune persistence immune response immunogenic immunogenicity analysis Immunological response intention-to-treat interval intervals ISRCTN ITT ITT analysis less Older participant persistence Pfizer/BioNTech platform priming randomised Randomly reactogenic reactogenicity reduced Registered SARS-COV-2 infection second dose significant difference significantly higher spike IgG study groups Support T-cell Response the vaccine titre Trial Vaccine Virus neutralisation [DOI] 10.1016/S2213-2600(22)00163-1 [Article Type] Randomized Controlled Trial
Low-dose self-amplifying mRNA COVID-19 vaccine drives strong protective immunity in non-human primates against SARS-CoV-2 infectionArticle Published on 2022-06-072022-10-04 Journal: Nature Communications [Category] COVID19(2023년), MERS, SARS, 변종, 임상, 진단, 치료기술, 치료법, [키워드] acute respiratory syndrome benefit boost cellular clinical trial convalescent coronavirus coronavirus disease COVID-19 COVID-19 vaccine dose doses driving effective vaccine Efficacy evaluated geometric mean titer GMT greater Heterologous highlighting homologous human sera humoral immune response immune response immunize low dose lower airways mice mRNA mRNA vaccine NAb neutralizing antibody non-human primate non-human primates offer pandemic populations prefusion prime-boost regimen Protective protective immunity provided reduction regimen regimens replicate rhesus macaque rhesus macaques RNA vaccines Safe SAM SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 vaccine spike glycoprotein Spread T cell response tested Translational immunology vaccination Vaccine viral replication [DOI] 10.1038/s41467-022-31005-z PMC 바로가기 [Article Type] Article
Omicron-specific mRNA vaccination alone and as a heterologous booster against SARS-CoV-2오미크론 특이적 mRNA 백신 단독 및 SARS-CoV-2에 대한 이종 부스터Article Published on 2022-06-062022-09-11 Journal: Nature Communications [Category] COVID19(2023년), MERS, SARS, 변종, 유전자 메커니즘, 임상, 진단, [키워드] animals Antibody Response assessment background level Beta binding antibody boost booster comparable delta variant elicit generate globe Heterologous homologous immune evasion in vivo increase injection LNP mice mRNA vaccination mRNA vaccine neutralization potency Neutralizing titer neutralizing titers omicron Omicron variant reduce reduction in responses against SARS-CoV SARS-CoV-2 These data titers vaccination Vaccine variant variant of SARS-CoV-2 [DOI] 10.1038/s41467-022-30878-4 PMC 바로가기 [Article Type] Article
Immunogenicity and safety of NVSI-06-07 as a heterologous booster after priming with BBIBP-CorV: a phase 2 trialBBIBP-CorV로 프라이밍한 후 이종 부스터로서의 NVSI-06-07의 면역원성과 안전성: 2상 시험Clinical Trial Published on 2022-06-062022-09-11 Journal: Signal Transduction and Targeted Therapy [Category] COVID19(2023년), MERS, SARS, 변종, 임상, 진단, [키워드] 1:1 Adverse reactions Alpha assigned BBIBP-CorV Beta boost booster booster vaccination conducted control groups coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 vaccine Delta double-blinded elicited followed by geometric mean geometric mean titer GMT GMTs group groups healthy Heterologous heterologous prime-boost homologous immunogenic immunogenicity immunogenicity assays inactivated increase Increases indicated individual Mild moderate Neutralizing neutralizing antibody omicron Omicron variant Participants Phase 2 phase 2 trial priming prototype randomised Randomly receive recipient Recombinant protein Safe safety profile SARS-CoV-2 SARS-CoV-2 variant significantly higher systemic adverse reaction three groups vaccination Vaccine variant VOCs [DOI] 10.1038/s41392-022-00984-2 PMC 바로가기 [Article Type] Clinical Trial
Six-month follow-up of a booster dose of CoronaVac in two single-centre phase 2 clinical trials2개의 단일 센터 2상 임상 시험에서 CoronaVac의 추가 용량의 6개월 추적Clinical Trial Published on 2022-06-032022-09-12 Journal: Nature Communications [Category] COVID19(2023년), MERS, SARS, 임상, 진단, 치료기술, [키워드] adverse event age Antibody titre booster booster dose clinical trial clinical trials contribute CoronaVac Determining dose double-blind Exploratory endpoints Follow-up follow-up period geometric mean titre GMT GMTs homologous humoral Immunity immunization immunization strategies increases in magnitude neutralising antibody neutralization Older placebo-controlled population immunity post-hoc analyses randomised recommendation recorded regimen Secondary endpoints titre [DOI] 10.1038/s41467-022-30864-w PMC 바로가기 [Article Type] Clinical Trial
Heterologous ChAdOx1/BNT162b2 vaccination induces stronger immune response than homologous ChAdOx1 vaccination: The pragmatic, multi-center, three-arm, partially randomized HEVACC trial이종 ChAdOx1/BNT162b2 예방 접종은 동종 ChAdOx1 예방 접종보다 더 강한 면역 반응을 유도합니다. 실용적인, 다기관, 3군, 부분 무작위 HEVACC 시험Randomized Controlled Trial Published on 2022-06-012022-09-11 Journal: EBioMedicine [Category] COVID19(2023년), MERS, SARS, 변종, 비임상, 임상, 진단, [키워드] 1:1 adaptive antibody Antibody titer Antibody titers approved Arm AstraZeneca B.1.617.2 BNT BNT162b2 breath ChAdOx1 comparable conducted COVID-19 COVID-19 vaccine Delta effective first dose Frequency group groups Heterologous Heterologous COVID-19 vaccination homologous immune response immunized immunogenicity induce interim analysis less median mRNA vaccine mRNA vaccines Neutralizing antibodies Neutralizing antibody titer neutralizing antibody titers NIAID participant Pfizer Pfizer/BioNTech Pragmatic primary endpoint Randomized reactogenicity regimen response SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 variants severe adverse events spike-specific T cell statistically significant stratified by sex supported T cell T cell responses T cells Trial university vaccination vaccination schedule Vaccine vaccinees Vaccines [DOI] 10.1016/j.ebiom.2022.104073 PMC 바로가기 [Article Type] Randomized Controlled Trial
Effectiveness of homologous and heterologous booster doses for an inactivated SARS-CoV-2 vaccine: a large-scale prospective cohort studyObservational Study Published on 2022-06-012022-10-04 Journal: The Lancet. Global health [Category] COVID19(2023년), SARS, 임상, [키워드] 95% CI adjusted Administered Admission Antigen approach AZD1222 BNT162b2 booster booster dose Booster vaccine calculated Cohort Complete confounders CoronaVac country COVID-19 COVID-19 vaccine Cox model death dose doses Effectiveness eligible evaluated Evidence excluded hazard ratios Heterologous homologous homologous or heterologous hospitalisation ICU admission inactivated individual individuals initiative intensive care laboratory-confirmed outcome outcomes Oxford-AstraZeneca participant Pfizer-BioNTech Policy Program prospective cohort study provide Regression model RT-PCR SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 vaccines Science severe disease Sinovac stratified study period Support survival symptomatic the vaccine vaccination vaccination schedule Vaccine vaccine dose [DOI] 10.1016/S2214-109X(22)00112-7 PMC 바로가기 [Article Type] Observational Study
SARS-CoV-2 DNA Vaccine INO-4800 Induces Durable Immune Responses Capable of Being Boosted in a Phase 1 Open-Label TrialSARS-CoV-2 DNA 백신 INO-4800, 1상 공개 라벨 시험에서 강화될 수 있는 내구성 면역 반응 유도Clinical Trial Published on 2022-06-012022-09-12 Journal: The Journal of Infectious Diseases [Category] Coronavirus, COVID19(2023년), MERS, SARS, 임상, 진단, [키워드] activated acute respiratory syndrome Adults adverse event age Antibody Response Antigen being booster booster dose CD8+ T cell clinical clinical trial coronavirus coronavirus disease COVID-19 DNA DNA vaccine dosage dose effective Electroporation evaluated Frequency full-length healthy homologous immune response immune responses immunogenicity increase in INO-4800 intradermal injection Mild MOST pandemic Participants Phase 1 primary dose response Safe Safety SARS-CoV-2 second dose Serious Adverse Events significantly increased subsequent Support T cell Trial Vaccine [DOI] 10.1093/infdis/jiac016 PMC 바로가기 [Article Type] Clinical Trial
Immunogenicity and safety of homologous and heterologous ChAdOx1-S and mRNA-1273 vaccinations in healthy adults in Taiwan대만의 건강한 성인에서 동종 및 이종 ChAdOx1-S 및 mRNA-1273 백신 접종의 면역원성과 안전성Article Published on 2022-06-012022-09-12 Journal: Journal of Clinical Virology [Category] COVID19(2023년), MERS, SARS, 진단, 치료기술, [키워드] Abbott Diagnostics age antibody production Antibody Response Antibody titer booster doses ChAdOx1-S collected COVID-19 COVID-19 vaccine COVID-19 vaccines cPass™ detection division Elecsys® Anti-SARS-CoV-2 S Genscript Germany healthy Heterologous heterologous prime-boost homologous Homologous and heterologous prime-boost regimens homologous or heterologous humoral immune response IgG immunogenicity induce Ireland Moderna mRNA-1273 Neutralizing New Participants priming regimen robust Roche Diagnostics Safe Safety safety profile SARS-CoV-2 SARS-CoV-2 IgG serum sample shown Sligo Taiwan USA vaccination Vaccine were given were measured [DOI] 10.1016/j.jcv.2022.105156 PMC 바로가기 [Article Type] Article
Design, immunogenicity, and efficacy of a pan-sarbecovirus dendritic-cell targeting vaccine범사르베코바이러스 수지상세포 표적화 백신의 설계, 면역원성 및 효능Article Published on 2022-06-012022-09-11 Journal: EBioMedicine [Category] COVID19(2023년), MERS, SARS, 변종, 진단, 치료법, [키워드] Antigen antigens antiviral efficacy B-cell epitope B-cell epitopes BNT162b2 CD40 conserved Coronaviruses COVID-19 cross-neutralizing antibodies cross-neutralizing antibody cross-reactive demonstrated dendritic cells Efficacy elicited ENhance Epitopes framework functional hACE2 homologous immunization immunogenic immunogenicity in vitro initiative K18-hACE2 transgenic mice Medicine MERS mice mRNA BNT162b2 vaccine Mutation Neutralizing antibodies nucleocapsid potency Pre-clinical model protein subunit vaccine recall Sarbecoviruses SARS-CoV-1 SARS-CoV-2 SARS-CoV-2 S spike Subunit vaccine supported surface receptor survival T-cell Response T-cell responses Vaccine variants of concern Viral viral control VoC VOCs [DOI] 10.1016/j.ebiom.2022.104062 PMC 바로가기 [Article Type] Article